Charles Schwab Investment Management Inc. grew its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 3.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,165,395 shares of the company’s stock after purchasing an additional 39,860 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.26% of Myriad Genetics worth $10,337,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Myriad Genetics by 520.8% in the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock valued at $40,000 after purchasing an additional 3,750 shares in the last quarter. CWM LLC raised its stake in shares of Myriad Genetics by 600.2% in the 1st quarter. CWM LLC now owns 9,796 shares of the company’s stock valued at $87,000 after purchasing an additional 8,397 shares in the last quarter. M.E. Allison & CO. Inc. acquired a new stake in shares of Myriad Genetics in the 1st quarter valued at about $93,000. Syon Capital LLC acquired a new stake in shares of Myriad Genetics in the 4th quarter valued at about $176,000. Finally, Blue Trust Inc. raised its stake in shares of Myriad Genetics by 57.0% in the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company’s stock valued at $127,000 after purchasing an additional 5,214 shares in the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.
Myriad Genetics Stock Up 3.3%
MYGN opened at $6.02 on Monday. The company’s 50-day moving average price is $5.15 and its 200 day moving average price is $7.13. Myriad Genetics, Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $29.30. The firm has a market cap of $560.10 million, a price-to-earnings ratio of -1.41 and a beta of 1.89.
Analyst Ratings Changes
View Our Latest Report on Myriad Genetics
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Further Reading
- Five stocks we like better than Myriad Genetics
- Dividend Capture Strategy: What You Need to Know
- Costco and Ross: 2 Ways to Play the Consumer Divide
- Stock Splits, Do They Really Impact Investors?
- Is Paramount Skydance a Buy Post-Merger, Short Squeeze?
- What is a support level?
- V2X Stock: Defense Underdog Riding a $4.3B Air Force Contract
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.